October 24, 2023
Orphelia Pharma applies to EMA its drinkable temozolomide medication in the treatment of relapsed or refractory neuroblastoma
Orphelia Pharma, a pharmaceutical company focused on pediatric and orphan medicines, has filed a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for KIZFIZO, the first oral liquid formulation of temozolomide.